Causaly Raises $60 Million In Series B Funding To Catalyze Ai-Powered Preclinical Discovery
07/13/23, 1:04 PM
Location
united kingdomMoney raised
$60 million
Industry
other
Round Type
series b
Investors
Olivier Pomel, Alex Gorsky, Visionaries Club, Pentech Ventures, Ebrd, Marathon Venture Capital, Index Ventures, Iconiq Growth
Causaly, the leading AI platform for biomedical research, closed $60m in Series B funding led by ICONIQ Growth, with participation from Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures and Visionaries Club. Strategic individuals also participated in the round, including Alex Gorsky (former Chairman and CEO of Johnson & Johnson) and Olivier Pomel (CEO and Co-Founder of Datadog). The latest round comes after the company recently tripled revenue and customers, now serving 12 of the top 20 pharma companies. The investment brings the total funding raised to $93 million, which will be utilized to extend Causaly’s product lead and expand commercial relationships, enabling breakthrough therapeutic innovations faster than ever before.
Company Info
Location
2 underwood row
united kingdom
Additional Info
Our mission at Causaly is to redefine the boundaries of human discovery by harnessing transformative AI technologies. Founded in 2018, Causaly’s unique AI platform is a powerful catalyst for the modern Life Science research organization, reshaping how data is found, analyzed and applied in critical decision-making processes in drug discovery and development.
Supporting a broad range of complex knowledge workflows, our platform accelerates the journey from bench research and laboratory insights to the launch of life-changing therapies.